HER2 Immunohistochemistry Testing May Not Be Needed in All Solid Tumours By Ogkologos - July 30, 2025 642 0 Facebook Twitter Google+ Pinterest WhatsApp Real-world experience from pan-tumour testing Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Generic Palbociclib Metastasis-Directed Therapy for Oligometastatic Solid Tumours in Histology-Specific Context ctDNA Testing After Neoadjuvant Chemotherapy and Radical Cystectomy Predicts Recurrence Risk in Patients with MIBC MOST POPULAR Sevabertinib Shows Antitumour Activity in Patients with Locally Advanced or Metastatic... November 14, 2025 Promising Results Observed with Front-line Sintilimab Plus a Bevacizumab Biosimilar in... November 21, 2020 An Intensive Follow-Up in Surgically Treated Patients for Endometrial Cancer Does... July 29, 2022 Darolutamide Delays the Spread of Some Prostate Cancers March 15, 2019 Load more HOT NEWS Managing Cancer Pain: Are Better Approaches on the Horizon? Mapping Cancer Genomic Evolution Offers Insights into Tumor Development Adding Lurbinectedin to First-Line Atezolizumab Maintenance Treatment Prolongs Survival Over Atezolizumab... Screening People at High Risk for Pancreatic Cancer May Help Them...
